BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
|Poll|February 11, 2021
Mini Quiz: Evaluating Dementia
Author(s)Priya Sharma, MD, Melinda Lantz, MD
Cognitive impairment is not always associated with dementia. For this reason, a full comprehensive history is an integral component of any assessment. Take the quiz to learn more.
Advertisement
Which of the following is not a cognitive reserve factor to consider in the evaluation of dementia?
Advertisement
Related to this article
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.
Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
2
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
3
Presenting Our November 2026 Theme: Emergency Psychiatry
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5